Convergent Therapeutics, Inc.
Kevin Zikaras is an accomplished professional in clinical development operations with extensive experience in the biotechnology and pharmaceutical sectors. Currently serving as Vice President of Clinical Development Operations at Convergent Therapeutics, Inc. since 2023, Kevin previously held the same title at TCR² Therapeutics Inc. from 2018 to 2023, where Kevin contributed significantly to building various clinical functions. Prior roles include Director of Clinical Development at Actinium Pharmaceuticals, Inc., Clinical Protocol Manager at Bristol-Myers Squibb, Clinical Research Manager at Columbia University Irving Medical Center, and Research Study Specialist at Memorial Sloan Kettering Cancer Center. Kevin holds an MBA from Cornell Johnson Graduate School of Management, an MS in Policy and Research - Healthcare Leadership from Weill Cornell Graduate School of Medical Sciences, an MS in Strategic Regulatory Affairs from Northeastern University, and a BA in Biology and Sociology from Bowdoin College.
This person is not in any teams
Convergent Therapeutics, Inc.
Convergent Therapeutics is a clinical-stage biotechnology company exploring the full potential of dual-targeted combination strategies to treat cancer. Convergent has developed a therapeutic platform that is capable of targeting validated and novel cancer antigens. Building on breakthrough research developed by Dr. Neil Bander at Weill Cornell Medicine, Convergent has demonstrated that dual targeting of surface cancer molecules like Prostate-Specific Membrane Antigen (PSMA) improves antitumor efficacy. By leveraging targeting agents with different bio-distributions, such as monoclonal antibodies and ligands, supra-additive therapeutic doses are delivered to tumor cells without additive toxicity to the patient.